venous catheter Articles
-
Costs Attributable to Arteriovenous Fistula and Arteriovenous Graft Placements in Hemodialysis Patients with Medicare coverage
Keywords Vascular access · Hemodialysis · Healthcare costs · Health economics · Arteriovenous fistula · Arteriovenous graft Abstract Introduction: Hemodialysis (HD) in end-stage renal disease (ESRD) patients requires vascular access (VA) through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter. While AVF or ...
-
Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access
Objective: Patients with end stage renal failure who require haemodialysis suffer morbidity and mortality due to vascular access. Bioengineered human acellular vessels (HAVs) may provide a haemodialysis access option with fewer complications than other grafts. In a prospective phase II trial from 2012 to 2014 (NCT01744418), HAVs were implanted into 40 haemodialysis patients at three sites in ...
-
LimFlow Percutaneous Deep Venous Arterialization
What interested you in LimFlow, and how did you get involved in the PROMISE I trial? Dr. Clair: Practicing vascular surgery, where a number of patients are evaluated for chronic limb-threatening ischemia (CLTI), you are guaranteed to have patients who are not candidates for percutaneous or surgical revascularization. These patients often have arterial systems open or identifiable to the ankle, ...
-
FDA Approved Peptide Drugs in the First Half of 2023
The FDA's Center for Drug Evaluation and Research (CDER) regulatory approval of a total of 26 NME (New Molecular Entity) drugs in the first half of 2023. It is worth noting that the 26 drugs approved include 4 peptide drugs, accounting for 15% of the total. In the past 2022, the FDA has approved only three peptide drugs: Tirzepatide, Lutetium 177Lu Vipivotide Tetraxetan and Terlipressin, of which ...
-
Why Sterile Packaging is Crucial for Medical Devices
Patients who need medical treatment often fear being exposed to harmful germs and unsanitary instruments. Just the thought of a healthcare provider using an unsterilized surgical device or needle is enough to make people feel queasy. As a result, patients find it reassuring to watch a clinician remove healthcare devices from sterile packaging before starting a procedure. Sterile packaging ...
-
Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Metaanalysis of Efficacy and Safety Outcomes
Background: Arteriovenous fistulae are the currently recommended gold standard vascular access modality for haemodialysis because of their prolonged patency, improved durability, and low risk of infection for those that mature. However, notable disadvantages are observed in terms of protracted maturation time, associated high rates of catheter use, and substantial abandonment rates. The aim of ...
-
What You Need to Know About Nutrition and Short Gut Syndrome
No parent wants to hear their child has a condition that might affect their education, family life, and overall well-being. Unfortunately, there’s currently no restorative treatment for short bowel syndrome (SBS). Monitoring nutrition is a lifelong necessity for anyone with this disorder. This means that no matter the cause of SBS, there are certain things you should know about nutrition ...
-
What is Total Parenteral Nutrition (TPN)
For patients and parents recently affected by or managing short bowel syndrome, TPN is likely new to their vocabulary. While any clinical acronym may sound overwhelming, TPN is not such a complicated one to understand. ...
-
Why auditing catheter dislodgement is a patient safety must
Chris Cheney at HealthLeaders Media released an article related to IV Catheter Dislodgement, the potential impact, and the need to audit these types of occurrences. The article focuses on Nancy Moureau’s work in understanding the impact of IV dislodgement, and ultimately a call to action: Records should be tracked with IV dislodgement reports as a mandatory effort, to continue to quantify ...
-
How One Smart MedTech Company is Leveraging Innovation to Save the Lives and Limbs of VTE Patients
Medical device start-up companies must focus on innovation, regulatory compliance, efficient processes and prudent financial management in order to survive. Smart MedTech companies prioritize their funding to only support innovation which will result in new products that fulfill significant unmet clinical needs over the long-term. Thrombolex, a relatively new entrant into the MedTech sector, is a ...
-
Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure
Abstract Acute decompensated heart failure remains the most common cause of hospitalization in older adults, and studies of pharmacological therapies have yielded limited progress in improving outcomes for these patients. This has prompted the development of novel device–based interventions, classified mechanistically based on the way in which they intend to improve central hemodynamics, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you